Cargando…

Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment

The use of targeted agents in the treatment of metastatic colorectal cancer (CRC) has improved patient outcomes. Anti-epidermal growth factor receptor (anti-EGFR) agents (cetuximab and panitumumab) and antiangiogenic molecules (bevacizumab, regorafeninb, ramucirumab, and aflibercept) have been succe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bignucolo, Alessia, De Mattia, Elena, Cecchin, Erika, Roncato, Rossana, Toffoli, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536012/ https://www.ncbi.nlm.nih.gov/pubmed/28708103 http://dx.doi.org/10.3390/ijms18071522

Ejemplares similares

Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy
por: De Mattia, Elena, et al.
Publicado: (2020)

Genetic biomarkers for hepatocellular cancer risk in a caucasian population
por: De Mattia, Elena, et al.
Publicado: (2017)

The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines
por: De Mattia, Elena, et al.
Publicado: (2019)

Pharmacogenetics Role of Genetic Variants in Immune-Related Factors: A Systematic Review Focusing on mCRC
por: Scarabel, Lucia, et al.
Publicado: (2022)

IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm
por: De Mattia, Elena, et al.
Publicado: (2021)

Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI
por: De Mattia, Elena, et al.
Publicado: (2019)

Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients
por: De Mattia, Elena, et al.
Publicado: (2018)

CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions
por: Roncato, Rossana, et al.
Publicado: (2020)

SMAD3 Host and Tumor Profiling to Identify Locally Advanced Rectal Cancer Patients at High Risk of Poor Response to Neoadjuvant Chemoradiotherapy
por: De Mattia, Elena, et al.
Publicado: (2021)

Pharmacogenomics and Personalized Medicine
por: Cecchin, Erika, et al.
Publicado: (2020)

FARMAPRICE: A Pharmacogenetic Clinical Decision Support System for Precise and Cost-Effective Therapy
por: Roncato, Rossana, et al.
Publicado: (2019)

New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach
por: Garziera, Marica, et al.
Publicado: (2019)

Sex Disparities in Efficacy in COVID-19 Vaccines: A Systematic Review and Meta-Analysis
por: Bignucolo, Alessia, et al.
Publicado: (2021)

Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation
por: Bignucolo, A., et al.
Publicado: (2023)

The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity
por: De Mattia, Elena, et al.
Publicado: (2023)

LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring
por: Canil, Giovanni, et al.
Publicado: (2023)

Association of HLA-G 3′UTR Polymorphisms with Response to First-Line FOLFIRI Treatment in Metastatic Colorectal Cancer
por: Scarabel, Lucia, et al.
Publicado: (2022)

Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC)
por: Garziera, Marica, et al.
Publicado: (2019)

An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer
por: Roncato, Rossana, et al.
Publicado: (2022)

Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS)
por: Garziera, Marica, et al.
Publicado: (2018)

Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis
por: Dalle Fratte, Chiara, et al.
Publicado: (2023)

The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure
por: Gagno, Sara, et al.
Publicado: (2023)

Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk
por: De Mattia, Elena, et al.
Publicado: (2022)

Predictive and Prognostic Value of Oncogene Mutations and Microsatellite Instability in Locally-Advanced Rectal Cancer Treated with Neoadjuvant Radiation-Based Therapy: A Systematic Review and Meta-Analysis
por: De Mattia, Elena, et al.
Publicado: (2023)

Circulating-Free DNA Analysis in Hepatocellular Carcinoma: A Promising Strategy to Improve Patients’ Management and Therapy Outcomes
por: Mezzalira, Silvia, et al.
Publicado: (2019)

Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma
por: De Mattia, Elena, et al.
Publicado: (2019)

Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L
por: Labriet, Adrien, et al.
Publicado: (2017)

HLA-G 3′UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer
por: Garziera, Marica, et al.
Publicado: (2017)

Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments
por: Bruera, Gemma, et al.
Publicado: (2020)

Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patients
por: Labriet, Adrien, et al.
Publicado: (2019)

A Panel of Tumor Biomarkers to Predict Complete Pathological Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer
por: Dalle Fratte, Chiara, et al.
Publicado: (2022)

Personalized antihypertensive treatment guided by pharmacogenomics in China
por: Xiao, Zhi-Lin, et al.
Publicado: (2022)

Genetic Diversity of the KIR/HLA System and Outcome of Patients with Metastatic Colorectal Cancer Treated with Chemotherapy
por: De Re, Valli, et al.
Publicado: (2014)

Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer
por: Ingle, James N
Publicado: (2008)

Pharmacogenomics of inhalational anesthetic agents
por: Nair, Abhijit S.
Publicado: (2019)

rs4143815-PDL1, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy
por: Zanusso, Chiara, et al.
Publicado: (2019)

Educating the Next Generation of Pharmacogenomics Experts: Global Educational Needs and Concepts
por: Just, Katja S., et al.
Publicado: (2019)

Predicting Agents That Can Overcome 5-FU Resistance in Colorectal Cancers via Pharmacogenomic Analysis
por: Huang, Tsui-Chin, et al.
Publicado: (2021)

Personalized medicine in breast cancer: pharmacogenomics approaches
por: Jeibouei, Shabnam, et al.
Publicado: (2019)

Pharmacogenomics: the promise of personalized medicine.
por: Hood, Ernie
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_09nnkd2bp9ljffim880hts4tol